Opus Genetics IRD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $11.98M-15.6% | $14.2M-3.0% | $14.63M-5.1% | $15.42M+13.0% | $13.65M+24.2% | ||
| —— | —— | —— | —— | —— | ||
| $21.58M-1.8% | $21.98M-9.9% | $24.39M+9.4% | $22.3M+12.1% | $19.89M+9.2% | ||
| $55.02M+4.2% | $52.8M-33.8% | $79.81M-0.6% | $80.29M+3.0% | $77.95M+6.7% | ||
| -$43.03M-11.5% | -$38.6M+40.8% | -$65.18M-0.5% | -$64.87M-0.9% | -$64.3M-3.6% | ||
| -359.1%-87.2pp | -271.9%+173pp | -445.4%-24.7pp | -420.7%+50.3pp | -471%+93.7pp | ||
| $198K+53.5% | $129K+89.7% | $68K— | $0— | $0— | ||
| $2.53M+27.2% | $1.99M-51.6% | $4.11M-0.8% | $4.14M-0.7% | $4.17M-6.7% | ||
| -$106.93M-116% | -$49.59M+27.3% | -$68.2M-17.0% | -$58.28M+0.6% | -$58.62M-1.9% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$106.93M-116% | -$49.59M+27.3% | -$68.2M-17.0% | -$58.28M+0.6% | -$58.62M-1.9% | ||
| -892.4%-543pp | -349.3%+117pp | -466.1%-88.2pp | -377.9%+51.5pp | -429.4%+94.0pp | ||
| -$1.33-62.2% | -$0.82+56.4% | -$1.88+2.1% | -$1.92+8.6% | -$2.10+2.3% | ||
| -$42.98M-11.5% | -$38.55M+40.8% | -$65.13M-0.4% | -$64.84M-0.9% | -$64.27M-3.6% | ||
| -358.7%-87.2pp | -271.5%+174pp | -445.1%-24.6pp | -420.4%+50.4pp | -470.8%+93.8pp | ||
| -$43.03M-11.5% | -$38.6M+40.8% | -$65.18M-0.5% | -$64.87M-0.9% | -$64.3M-3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Opus Genetics's revenue?
- Opus Genetics (IRD) generated $12.0M in revenue over the trailing twelve months, down 12.2% year over year.
- Is Opus Genetics profitable?
- Opus Genetics is not currently profitable: it reported a net loss of $106.9M over the trailing twelve months, a -892.4% net margin.
- What is Opus Genetics's earnings per share?
- Opus Genetics's diluted EPS over the trailing twelve months is $-1.33.
- Where does Opus Genetics's income statement data come from?
- Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
